3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Melanoma
3
Brain Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Colorectal Neoplasms
2
Advanced Cancer
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Interventions
Letrozole
3
Fulvestrant
3
exemestane
2
Trastuzumab
2
Irinotecan
2
Docetaxel
2
Capecitabine
2
Anastrozole
2
ribociclib
1
palbociclib
1
irinotecan sucrosofate
1
abemaciclib
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Liposomes
1
Everolimus
1
Cyclophosphamide
1
Cell Separation
1
Aromatase Inhibitors
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Cancer Metastatic
×
abemaciclib
×
Clear all
NCT04603183
2025-12-12
ABIGAIL
MedSIR
Phase 2
Completed
162 enrolled